智通财经APP讯，复星医药(02196)公布，因工作安排调整，吴以芳先生、王可心先生分别辞去公司董事长、联席董事长职务。
鉴于日后工作的安排，同意自本决议出具之日起，吴以芳先生由执行董事改任非执行董事、王可心先生将继续担任执行董事;同时，同意陈玉卿先生由非执行董事改任执行董事，并选举陈玉卿先生担任第九届董事会董事长、关晓晖女士担任第九届董事会联席董事长(不再担任副董事长)、文德镛先生担任第九届董事会副董事长，上述任职变动均自2025年4月29日起生效。
根据《公司章程》的规定，董事长为公司的法定代表人，公司的法定代表人将变更为陈玉卿先生。
因工作安排调整，吴以芳先生辞去《香港联合交易所有限公司证券上市规则》3.05条项下的公司授权代表。同意聘任陈玉卿先生为公司授权代表，与公司联席公司秘书之一的陈秀玲女士共同履行联交所《上市规则》项下授权代表的有关职责。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.